Medical treatment of breast cancer with boric acid materials
First Claim
Patent Images
1. A method for the treatment of breast cancer cell lines selected from the group consisting of ZR-75-1 and SK-BR-3, the method comprising:
- identifying the presence of at least one of breast cancer cell lines ZR-75-1 and SK-BR-3 in a patient; and
providing a solution of boric acid or boric acid salts to the patient in a manner that delivers boric acid or boric acid salt to breast cancer cells in the patient.
1 Assignment
0 Petitions
Accused Products
Abstract
Breast cancer cell lines selected from the group consisting of ZR-75-1 and SK-BR-3 are treated by a method comprising: identifying the presence of at least one of breast cancer cell lines ZR-75-1 and SK-BR-3 in a patient; and providing a solution of boric acid or boric acid salts to the patient in a manner that delivers boric acid or boric acid salt to breast cancer cells in the patient.
-
Citations
14 Claims
-
1. A method for the treatment of breast cancer cell lines selected from the group consisting of ZR-75-1 and SK-BR-3, the method comprising:
-
identifying the presence of at least one of breast cancer cell lines ZR-75-1 and SK-BR-3 in a patient; and
providing a solution of boric acid or boric acid salts to the patient in a manner that delivers boric acid or boric acid salt to breast cancer cells in the patient. - View Dependent Claims (2, 3, 4, 5, 6, 7, 11, 14)
-
-
8. A method for the treatment or prevention of breast cancer cell lines comprising
providing boric acid or boric acid salts to the patient in a manner that delivers boric acid or boric acid salt to breast cancer cells and the breast region of a patient.
-
12. A method for the treatment of breast cancer cell lines selected from the group consisting of ZR-75-1 and SK-BR-3, the method comprising:
-
identifying the presence of at least one of breast cancer cell lines ZR-75-1 and SK-BR-3 in a patient; and
providing a solution of organic boron compound to the patient in a manner that delivers the organic boron compound to breast cancer cells in the patient.
-
Specification